Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain

Molecular and Cellular Biology

Volumn 19, Issue 5, 1999, Pages 3395-3402

  Selivanova, Galina ^a   Ryabchenko, Ludmila ^a   Jansson, Emmelie ^b   Iotsova, Violetta ^c   Wiman, Klas G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; PROTEIN P53;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY;

EID: 0032911047     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.19.5.3395     Document Type: Article

References (28)

1. Abarzua, P., J. E. LoSardo, M. L. Subler, R. Spathis, Y.-A. Lu, A. Felix, and A. Neri. 1996. Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene 13:2477-2482.
2. Bakalkin, G., G. Selivanova, T. Yakovleva, E. Kiseleva, E. Kashuba, K. P. Magnusson, L. Szekely, G. Klein, L. Terenius, and K. G. Wiman. 1995. p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Res. 23:362-369.
3. Bargonetti, J., J. J. Manfredi, X. Chen, D. R. Marshall, and C. Prives. 1993. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild type but not from oncogenic mutant p53 protein. Genes Dev. 7:2565-2574.
4. Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355.
5. Clore, G. M., J. G. Omichinski, K. Sakagushi, N. Zambrano, H. Sakamoto, E. Apella, and A. M. Groneborn. 1994. High resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 245:386-391.
6. Gu, W., and R. G. Roeder. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606.
7. Halazonetis, T. D., L. J. Davies, and A. N. Kandil. 1993. Wild-type p53 adopts a "mutant"-like conformation when bound to DNA. EMBO J. 12: 1021-1028.
8. Halazonetis, T. D., and A. N. Kandil. 1993. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J. 12:5057-5064.
9. Hupp, T. R., D. W. Meek, C. A. Midgley, and D. P. Lane. 1992. Regulation of the specific DNA binding function of p53. Cell 71:875-886.
10. Hupp, T. R., D. W. Meek, and C. A. Midgley. 1993. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res. 21:3167-3174.
11. Hupp, T. R., and D. P. Lane. 1994. Allosteric activation of latent p53 tetramers. Curr. Biol. 4:865-875.
12. Hupp, T. R., A. Sparks, and D. P. Lane. 1995. Small peptides activate the latent sequence-specific binding function of p53. Cell 83:237-245.
13. Jayaraman, L., and C. Prives. 1995. Activation of p53 sequence specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81:1021-1029.
14. Kern, S. E., J. A. Pietenpol, S. Thagaligam, A. Seymour, K. W. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:821-832.
15. Ko, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054-1072.
16. Lee, W., T. S. Harvey, Y. Yin, P. Yau, D. Litchfield, and C. H. Arrowsmith. 1994. Solution structure of the tetrameric minimum transforming domain of p53. Nat. Struct. Biol. 1:877-890.
17. Muller-Tiemann, B. F., T. D. Halazonetis, and J. J. Elting. 1998. Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. Proc. Natl. Acad. Sci. USA 95:6079-6084.
18. Pavletich, N. P., K. A. Chambers, and C. O. Pabo. 1993. The DNA binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7:2556-2564.
19. Selivanova, G., V. Iotsova, E. Kiseleva, M. Ström, G. Bakalkin, R. C. Grafström, and K. G. Wiman. 1996. The single stranded DNA end binding site of p53 coincides with the C-terminal regulatory region. Nucleic Acids Res. 24:3560-3567.
20. Selivanova, G., V. Iotsova, I. Okan, M. Fritsche, M. Ström, B. Groner, R. C. Grafström, and K. G. Wiman. 1997. Restoration of the growth suppressor function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3:632-638.
21. Selivanova, G., L. Ryabchenko, and K. G. Wiman. Unpublished data.
22. Shanlian, E., A. Zauberman, D. Ginsberg, and M. Oren. 1992. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol. 12:5581-5592.
23. Shaw, P., J. Freeman, R. Bovey, and R. Iggo. 1996. Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene 12:921-930.
24. Stürzbecher, R-W., R. Brain, C. Addison, K. Radge, M. Remm, M. Grimaldi, E. Keenan, and J. R. Jenkins. 1992. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7:1513-1523.
25. Unger, T., M. M. Nau, S. Segal, and J. D. Minna. 1992. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 11:1383-1390.
26. Wang, Y., M. Reed, P. Wang, J. E. Stenger, G. Mayr, M. E. Anderson, J. F. Schwedes, and P. Tegtmeyer. 1993. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev. 7:2575-2586.
27. Waterman, J. L. F., J. L. Shenk, and T. D. Halazonetis. 1995. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J. 14:512-519.
28. Wleczorek, A. M., J. L. F. Waterman, M. J. F. Waterman, and T. D. Halazonetis. 1996. Structure-based rescue of common tumor-derived p53 mutants. Nat. Med. 2:1143-1146.